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Abstract 
Identifying the intracellular targets of small molecules ² target ID ² is a major problem in chemical 
biology with broad application to the discovery and development of novel therapies. Traditional target 
ID studies have relied on drug-affinity chromatography to separate biological mixtures combined with 
mass spectrometry shotgun sequencing for peptide identification. This workflow is limited, however, by 
low specificity for unique peptides, high demand for cellular material, unknown depth of profiling, and 
other problems. To address these problems, we explore and describe here a novel strategy for cell lysis 
and drug-DIILQLW\WKDWZHFDOO´IOXRURXVSURWHRPLFVµ%\FRQMXJDWLQJDVPDOOPROHFXOHWRDSHUIOXRULQDWHG
alkane, we hypothesized that we could achieve superior recovery, specificity, and identification, allowing 
us to identify previously unknown drug targets with drug-affinity methods. We establish the conditions 
for fluorous proteomics and synthesize fluorinated probes for two drugs as a proof-of-concept. 
Lenalidomide, a derivative of thalidomide with unknown intracellular targets but widespread clinical use, 
is investigated and novel binders are identified. A particular derivative, 5HPP33, is singled out for 
potential future drug development. JQ1, an inhibitor of BET bromodomains in development as a 
treatment for hematological malignancies, is used to compare biotinylated versus fluorous tags and to 
identify new binders of possible therapeutic relevance. We conclude that fluorous proteomics retains 
high potential as an alternative to traditional drug-affinity chromatography strategies and may aid in 
target ID going forward, but is not without complications.
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Introduction 
Genomics and drug discovery 
It is commonly asserted that genomics and other high-throughput technologies have revolutionized the 
practice of biology, and that they offer the surest way forward for understanding and treating many of 
our most pressing medical concerns ² diseases such as diabetes, cancer, HIV, autoimmune disorders, 
and more (Collins et al., 2003). Yet the post-genomic explosion of data in biology has, by at least one 
measure, been resolutely resistant to practical application in the clinic: the yearly approval of new drugs 
has stayed the same or markedly declined in the last fifteen years (Horrobin 2001; Milne, 2003). Drug 
discovery, an inherently stochastic and slow process, has simply not kept up with the exponential growth 
VHHQHOVHZKHUHLQWKLV´UHYROXWLRQµof the biological sciences.  
This is not to say that there have not been major successes in deploying new drugs in the clinic. 
Targeted therapies such as Gleevec (Bucdunger et al., 1996; Druker et al., 1996) and biologicals such as 
bevacizumab, to name just two well-known cancer treatments that came to market in the last fifteen 
years, have brought many more previously-UHIUDFWRU\GLVHDVHVXQGHUWKHKHDGLQJRI´WUHDWDEOHµ6WLOOWKH
QHZWDUJHWHGRU´UDWLRQDOO\GHVLJQHGµWKHUDSLHVKDYHQRWHVFDSHGWKHROG$Fhilles heels of resistance 
(especially with quick-evolving targets like cancer cells or some viruses) or off-target effects (Quintas-
Cardama et al., 2007). Considering that there are perhaps hundreds of thousands of different expressed 
proteins, splice isoforms, post-translational modifications, and mutants ² it is estimated that there are 
3,000 to 10,000 druggable targets in the human proteome (Overington et al., 2006) ² the fact that only 
roughly 500 proteins are currently exploited by a drug in any form is remarkable (Meisner et al., 2004). 
Even in a disease with a putatively well-established target, the preclinical data that leads to investigatory 
drug development can sometimes be misleading (Begley and Ellis, 2012), and extremely careful, direct 
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validation of targets is required beyond the circumstantial evidence that is often supplied in the literature 
from single experiments (Prinz et al., 2011). At the same time, once a target is well-validated, screens of 
hundreds of thousands of compounds can fail to yield any notable hits ² perhaps because we do not 
capture the full chemical space (Hert et al., 2009) ² though some progress has been made in chemical 
diversification of libraries (Schreiber, 2000). However much of a role is played by any of these specific 
limitations of biology or chemistry, the relative poverty of drug development is beginning to look 
particularly glaring when one can, for instance, enumerate to a patient the entirety of the mutation 
spectrum in their tumor and yet lack even a single chemical entity to hit any of the targets the 
sequencing presents. Innovation in the discovery of new drugs is now, perhaps for the first time, the 
major bottleneck to current medical progress in a large number of diseases.  
 
Target identification  
The first step in most projects of drug discovery is the search for a druggable target, such as might be 
implied by the mutations present in tumor DNA or the proteins packaged in a virus. The next step is an 
attempt to find a molecule which hits that target. Flipping this problem over, once in possession of a 
biologically active compound, we may not know all of the proteins to which it binds in a cell. This 
knowledge is crucial for understanding side-effect profiles, pharmacokinetics, further drug development, 
and more. The discovery of mechanistically-relevant targets for in-hand compounds is generally termed the 
SUREOHPRIGUXJ´WDUJHWLGHQWLILFDWLRQµ 
Target ID may be performed on compounds of unknown or known medical effects. In the case 
of small molecules with unknown or merely suspected clinical relevance, target ID may be performed as 
a follow-up to hits on phenotypic screens (Bredel and Jacoby, 2004), or for investigation based on 
chemical similarity to known drugs (Savchuk et al., 2004 Schuffenhauer et al., 2003), or as a part of drug 
derivatization for investigational or medical use (Frye, 2010). Computer modeling and structural 
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chemistry can play a key role (Laggner et al., 2011), and innovative approaches combining proteomics, 
computation, and molecular biology are consistently being applied (see for instance Wacker et al., 2012).  
Where drugs have known therapeutic utility but unknown cellular targets, target ID can have additional 
implications. A drug with a known use (say as an empirically-derived malaria treatment) can be 
employed to identify a novel protein target (perhaps a protein critical to parasite invasion), thus spurring 
new drug development (structurally similar drugs for the same target, or new screens). That same drug 
may be used to identify promiscuous binding to other proteins that may generate side-effects, paving the 
way for new development to reduce this off-target binding, or even utilize off target effects for further 
avenues of development. Protein complexes can be purified and new targets with the same mechanistic 
principles can be pursued (inhibiting different members of a transcriptional complex, for instance). Thus 
target ID on compounds of known medical use can leverage chemical biology for the discovery of new 
biological knowledge, new lines of drug development, and new clinical information ² all at once. 
Remarkably, given the paucity of successful targeted therapies, a significant number of drugs that 
are actively prescribed in a clinical setting in fact have no known cellular targets. Two influential reviews 
have argued that somewhere between 7 (Drews, 2000) and 21 (Overington et al., 2006) percent of all 
FDA-approved drugs have no known primary target or mechanism of action, even while they have 
clearly demonstrated therapeutic value. This estimate may be, to a certain extent, an exaggeration or an 
easily-remedied quirk of the methods most commonly employed in drug discovery (Gregori-Puigjane et 
al., 2012), but it is nonetheless clear that in a strikingly large number of cases, we lack complete 
information about which intracellular targets of a clinically-relevant small molecule are therapeutically 
relevant, which generate side-effects, and which are merely hangers-on. Importantly, this problem is not 
limited to a single disease, or single class of molecules: drugs with unknown directly-bound targets 
include Halofantrine, an anti-malarial; antibiotics such as 4-aminosalycilic acid (TB) and clofazimine 
(leprosy); anesthetics such as haltothane and diethyl ether (the oldest known!); the now-widely-used anti-
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convulsant levetiracetam (keppra); and even the diabetes drug metformin, though some advances have 
been made in elucidating its mechanism (Miller et al., 2012) has few known direct binders (Imming 
2006).  
 
Chemical proteomics and drug-affinity chromatography 
Target ID for known medical compounds is therefore a major biological and clinical problem as well as 
a unique opportunity. Classically, several methods have been employed for the discovery of drug targets: 
activity-based probe profiling, which focuses particularly on the activity of a protein family in response 
to a drug (Jaeger et al., 2004; Barglow and Cravatt, 2007); analysis of changes in cellular composition due 
to drug treatment, such as by microarray or proteomics (see for instance Eggert et al., 2004; Kuruvilla et 
al., 2002); and compound-centric chemical proteomics, which consists of traditional drug affinity 
chromatography to purify and identify drug-binding molecules (reviewed in Rix and Furga, 2009).  
Drug-affinity chromatography methods have been used for target ID for decades with significant 
success (Cuatrecasas et al., 1970; Harding et al., 1989; Sabatini et al., 1994). The essential idea of drug 
affinity proteomics is to extract a proteome from a cell lysate of interest, separate out the mixture based 
on affinity for the drug, bind the drug-protein complex to a stable matrix, wash away unbound proteins, 
elute, and identify peptides that bound the drug (Figure 1A). Innovations in drug chromatography have 
made it almost the procedure of choice for Target ID (Rix 2004). The identification of proteins has in 
particular benefited from the deployment of mass spectrometry (MS) techniques with higher sensitivity, 
through innovations such as nano-electrospray ionization (ESI) (Wilmm and Mann, 1996), high-
performance liquid chromatography (HPLC), and high resolution spectrometers (Hoffman, 2005). 
Combining these advances with stable isotope labeling (Ong et al., 2002) or other tags (Aggarwal, et al., 
2006; Ross et al., 2004) and the wide availability of protein databases and bioinformatics has led to more 
reliable quantification and identification. These advances have been used to greatly improve the 
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sensitivity of target drug discovery (Belcher et al., 2012; Chen et al., 2010). Target identification has been 
performed using LC-MS drug affinity chromatography for antibiotics (Schug et al., 2011), kinase 
inhibitors (Bantscheff et al., 2007; Brehmer et al., 2004; Godl et al., 2005; Rix et al., 2007), and more. 
While MS-based drug affinity experiments have several advantages ² the identification is roughly 
unbiased, proteome-wide and requires only native cellular lysate ² they have also been plagued by 
significant limitations. There is high demand for cellular material, and lysis conditions may not sample 
each compartment of the cell equally; conventional extraction methods often bias cytosolic protein 
recovery, and deeper profiling can necessitate the use of harsh reagents which can denature complexes 
and mask important protein-drug and protein-protein interactions (Vodisch et al., 2009). There are 
sample throughput limitations, especially in the case of quantification and many non-specific binders. 
Non-specific interactions to the drug-affinity matrix are common and can confound results by washing 
out signals from proteins of more biological importance (Bantscheff et al., 2011). The choice of matrix is 
in turn related to the choice of tag employed on the small molecule, which brings its own concerns. A 
tag or linker that is too large can interfere with native protein binding, while the chemical modulation of 
a drug required to tag it may alter its own chemical properties. So as to minimize these concerns, 
chemical derivatization must be carefully related to structural activity data, say from a structure-activity 
relationship series (SAR). An SAR may not always be rigorously known ² and even when it is, chemical 
alteration of a drug may still involve guesswork. Finally, since recovery of material is proportional to both 
protein-drug affinity and protein abundance (Graves and Wu, 1974), high-affinity and biologically-
important binders that are in low cellular abundance may be weak ´hitsµLQDWUDGLWLRQDOVFUHHQ due to 
this bias.  
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Fluorous proteomics for target ID 
7KHFRPELQDWLRQRIWKHVHGHILFLHQFLHVPLJKWEHSUHGLFWHGWROHDGWRVLJQLILFDQW´EOLQG-VSRWVµLQGUXJ-
affinity chromatography target ID experiments. These blind spots might also go some length to 
explaining a deficiency in existing methods of drug discovery and development: if the most commonly 
used unbiased method to detect drug-protein interactions in the laboratory has methodological 
difficulties, all aspects of drug discovery and development are likely to be correspondingly more 
difficult.  
Consequently, in the work presented here, we chose two cancer drugs ² one in active use in the 
clinic and one in clinical development (with widespread use as a chemical probe) ² and applied new 
method development for target ID as well as the initial steps of further drug discovery. In taking this 
approach, we hoped to demonstrate the feasibility of new technological applications to drug discovery-
focused proteomics, as well as to use these new approaches on interesting drugs as a proof-of-concept. 
Our method development was focused on increasing the sensitivity and specificity of target ID. One of 
the major limitations of affinity chromatography, cited above, is excess binding of proteins to resin, 
linker, or other requirements of the experimental set up which depart from the normal in vivo 
environment of the drug-protein interaction. In nearly all experiments, small molecules of interest are 
conjugated, usually via long hydrophobic linker, to some tag which has specificity for a corresponding 
resin (see Figure 1A). The most commonly used tag-resin pair is a biotin tag and streptavidin resin, 
though this is by no means the only choice. Nearly all resins share in common, however, a descent from 
biological systems ² streptavidin is itself a protein ² and consequently they generate many non-specific 
protein interactions with the resin itself. The sheer weight of non-specific binders to such resins can 
overwhelm any signal from truly unique drug-protein interactions. We therefore began by searching for 
a resin which has suitable properties for drug-affinity chromatography ² separation capabilities under 
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normal solvent conditions, suitably small tags, ease of chemical modification, etc. ² which might also 
minimize non-specific interactions with the protein lysate.  
:HFKRVHWRLQYHVWLJDWH´IOXRURXVWDJVµ)OXRURXVWDJVZKLFKKDYHEHHQLQXVHIRUVHYHUDO\HDUV
in synthetic organic chemistry settings, make use of the unique properties of perfluorinated alkanes 
(Gladysz et al., 2006). The motivation for fluorous chemistry is derived from the observation that 
perfluorinated solvents dissolve perfluorinated molecules better than either aqueous or organic solvents, 
while excluding non-fluorinated organic compounds and solvents ² thus allowing for rapid purification 
and separation of a single compound in a synthetic setting (Dobbs and Kimberley, 2002). The initial use 
RIIOXRURXVFKHPLVWU\ZDVLQ´ELSKDVLFµV\VWHPV+RUYDWKDQG5DEDLLQZKLFKDUHDFWLRQFRXOG
RFFXULQD´PL[HGSKDVHµRIIOXRURXVDnd another liquid phase which had limited or no solubility in 
fluorous phases, such as organic solvents. While organic and fluorous phases readily intermixed at a 
FHUWDLQWHPSHUDWXUHWKH\WKHQUHVROYHGLQWRWZRSKDVHVZKHQFRROHG7KLV´LQ-EHWZHHQµSURSHUty of 
fluorinated molecules allowed for reactions to occur at the fluorous phase or at the interface of the 
phases, but only the desired product was retained in the fluorous phase (or at least the two separated 
reaction products in a predictable manner, allowing one to choose which products of the reaction to 
carry forward).  
The facile separation of products from reactants and catalysts under mild conditions initiated 
JUHDWLQWHUHVWLQV\QWKHWLFVHWWLQJVVRRQWKHFRQFHSWRID´SRQ\WDLOµ² which was eventually renamed a 
´IOXRURXVWDJµ² evolved (Gladysz and Curran, 2002). In typical use, a molecule which commonly has 
normal organic reactivity ² and is consequently soluble in conventional organic solvents ² can be 
´WDJJHGµZLWKDSHUIOXRULQDWHGDONDQHZKLFK confers preferential solubility in fluorous phases but retains 
the reactivity of the original organic molecule. Synthetic reactions can be carried out, and, during 
extraction, a fluorous solvent can rapidly and easily purify only the fluorous molecule, just as in 
traditional biphasic fluorous systems (Zhang, 2006). This eliminates the need for complex fluorination 
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and allows for a predictable, modular approach to separation and reaction purification. Since its early 
uses, fluorous chemistry has evolved to include solid silica-based fluorinated phases for use in typical 
applications such as HPLC, solid-phase purification, microarray immobilization, and more.   
Drawing inspiration from the use of fluorous chemistry in such synthetic settings, we hypothesized that 
a fluorous-tagged small molecule might be reliably recovered from a complex protein mixture by 
ELQGLQJWRWKHIOXRURXVUHVLQWKHUHE\UHSOLFDWLQJWKHW\SLFDO´ELRWLQ\ODWHG-FRPSRXQGVWUHSWDYLGLQUHVLQµ
strategy employed in drug affinity chromatography. In addition to the ease of use and simplicity that 
such a method might have (this is the advantage which already increased its popularity in the synthetic 
organic chemistry setting), we also hypothesized that such a resin-linker combination might generate a 
much lower rate of non-specific effects due to the elimination of proteins or biological-like molecules 
(such as the common His tag) from the resin-tag pair. This in turn would greatly increase the specificity 
of target ID experiments. We call this apprRDFK´IOXRURXVSURWHRPLFVµDQGHPSOR\HGLWKHUHIRUWKH
investigation of two compounds of interest.  
 
Lenalidomide and target ID 
We chose two cancer drugs to test fluorous proteomics target ID: the multiple myeloma drug 
lenalidomide (revlimid) and the experimental bromodomain inhibitor JQ1. Lenalidomide is in current 
clinical use and in several clinical trials for an expanding sphere of indications. JQ1 is a first-in-class drug 
with widespread laboratory use as a probe and early investigation as both a cancer drug and 
contraceptive.   
Lenalidomide, which is a derivatives of thalidomide, is one of the so-FDOOHG´LPPXQRPRGXODWRU\
drugsµ,0L'V7KDOLGRPLGHZKLFKZDVLQLWLDOO\REVHUYHGWRKDYHDQWL-inflammatory but T-cell 
boosting properties (from which it gets the IMiD label), is perhaps one of the most historically 
interesting drugs in recent medical history. It was widely prescribed as a sedative in the 1950s until it was 
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found to have grossly teratogenic properties, which engendered a scandal that birthed the modern form 
of the FDA-XGDK)RONPDQLGHQWLILHGWKDOLGRPLGHDVDQLQKLELWRURIDQJLRJHQHVLVLQ'·$PDWRet 
al., 1994) after which it was tried as a myeloma drug and found to have significant efficacy in patients. A 
derivative of thalidomide with a single amine on the phthalimide group, known as lenalidomide, was 
found to increase the potency RIWKDOLGRPLGH·VDQWL-myeloma effect several fold in vitro and have 
increased efficacy in vivo as well (Palumbo et al., 2012). A combination of glucocorticoid (prednisone or 
dexamethasone), proteasome inhibitors like bortezomib, and a thalidomide analog like lenalidomide is 
now commonly the frontline treatment for multiple myeloma (Palumbo et al., 2010).  
But no satisfactory consensus exists as to the mechanism of the anti-tumor effect of thalidomide 
analogs (Singhal et al., 1999; Ching et al., 2007) or an exact list of cellular targets they bind. The drug has 
known cell-autonomous effects on apoptosis (Hideshima et al., 2000), but it is also anti-angiogenic 
'·$PDWRet al., 1994), alters extracellular matrix remodeling (Geitz et al., 1996), suppresses production 
of tumor necrosis factor alpha while increasing IL-2 production (Sampaio et al., 1991), and has a hand in 
changing expression and response to various other cytokines (Corral et al., 1996; Haslett et al., 1998). 
Thalidomide and its analogs have been reported to have clear cell-autonomous effects in vitro, but the 
dosage at which these effects takes place does not appear to be within the therapeutic concentration 
given to patients in simple models (Chung et al., 2004). Thus significant questions about the mechanism 
of lenalidomide have long been part of its mystery.  
Recently, both before and after this work was completed, significant strides have been made 
towards elucidating the mechanism of lenalidomide. When this work was initially started, the most well-
known effect of thalidomide, its teratogenicity, had EHHQWUDFHGWRWKDOLGRPLGH·VELQGLQJDQGLQKLELWLRQ
of cereblon (CRBN) ² a component of the E3 ubiquitin ligase complex ² with subsequent modification 
of developmental pathways such as the down-regulation of fibroblast growth factors (Ito et al., 2010). 
CRBN was identified as a binder of thalidomide in the original study by traditional target ID methods, 
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and downregulation of CRBN in zebrafish and chick models was found to mimic the effects of 
thalidomide in those species. Other work immediately following this connected CRBN with 
WKDOLGRPLGH·VDQWL-tumor effect, but the evidence was indirect (Zhu et al., 2011). Because of the close 
resemblance of thalidomide and lenalidomide, it was natural to hypothesize that CRBN did indeed 
underlie the effect and that target ID would identify it as a binder of lenalidomide as well. But 
lenalidomide is not nearly as teratogenic as thalidomide in previously tested models (Barlett et al., 2004), 
implying some difference in mechanism between lenalidomide and thalidomide.  
Since the work below was completed, the mechanism of lenalidomide has been fleshed out in 
novel and highly influential work which, in a way, proves the point that target ID can reveal novel 
biology as much as novel drug design. Two studies, using vastly different experimental designs, reported 
that lenalidomide does, in fact, bind cereblon in myeloma cell lines (Kronke et al., 2014; Lu et al., 2014). 
The binding of lenalidomide to cereblon initiates a selective and novel ubiquitination of two immune-
cell development transcription factors from the Ikaros family, Ikaros (IKZF1) and Aiolos (IKZF3). 
After binding to cereblon in the presence of lenalidomide, these proteins are rapidly degraded, while 
other nearly-homologous members of the Ikaros family (IKZF2, 4 and 5) were unaffected, and selective 
mutation of certain residues in Ikaros and Aiolos to look more like other family members could 
abrogate the anti-proliferative effect of lenalidomide. Interestingly, both these transcription factors are 
critical for normal plasma cell development and loss of function mutations have been associated with 
acute lymphoblastic leukemia. IKZF loss also led to decreased expression of IRF4, which had been seen 
in prior experiments with lenalidomide (Yang et al., 2012), and is a known repressor of IL-2, explaining 
OHQDOLGRPLGH·VHIIHFWRQRWKHULPPXQHFHOOV7KHVHWZRSDSHUVWKHUHIRUHSRLQWHGWRQRWRQO\DQRYHO
mechanism of action for lenalidomide, but perhaps a novel mechanism of action in all of drug discovery: 
selectively altered ubiquitination. A further recent paper solved the crystal structure of CRBN-DDB1 in 
complex with lenalidomide, and could therefore lead to design programs aimed at hitting previously 
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´XQGUXJJDEOHµWDUJHWVE\PRGXODWLRQRIXELTXLtination (Chamberlain et al., 2014). While the solution to 
the lenalidomide mystery has therefore been by and large resolved, many questions remain, and some of 
the work presented below may still induce useful directions of investigation in this regard.  
JQ1 and target ID 
JQ1 ² in contrast to lenalidomide ² is not a widely used clinical drug but is a first-in-class inhibitor of 
the bromodomain and extra terminal (BET) family of proteins (Filippakopoulos et al., 2010) which has 
widely reported potential in hematological malignancies%(7SURWHLQVZKLFKDFWDV´DGDSWRUVµRQ
acetylated histones to recruit polymerases and activate transcription, have recently been identified as 
playing a major role in the pathogenesis of some cancers (Zuber et al., 2011), and BET inhibition is a 
promising strategy for rewiring the transcriptional profile of many cell types to a quiescent state, leading 
to the investigation of JQ1 as a potential male contraceptive through the inhibition of sperm maturation 
(Matzuk et al., 2012). The mechanism of JQ1 as an anti-cancer agent is novel, and likely involves a highly 
unique selective downregulation of the transcription of c-Myc, a well-known oncogene in many varieties 
of cancer, via a profound depletion of transcriptional machinHU\IURP´VXSHU-HQKDQFHUµFLWHVLQWKH
genome (Lovén et al., 2013). 
The strongest protein binders of JQ1 are known, and JQ1 and other BET inhibitors have been 
used extensively as a chemical probe to find members of the histone reading complex (Dawson et al., 
2011). None of these experiments, however, have been as robust as an unbiased mass-spectrometry 
based screen. We therefore chose to investigate JQ1 because the robust proteomics data already 
available on JQ1 and similar drugs would allow a ready comparison between our technique and 
previously applied proteomics techniques. In addition, reports of new effects of JQ1 on various cancer 
cell lines are continually being produced (Ott et al., 2012), and we generate data here for the first time on 
JQ1 treatment in leukemia cell lines in which JQ1 is reported to have unique effects.  
 
17 
 
Materials and Methods 
Reagents 
All reagents were of ACS grade, and obtained from Thermo Scientific, unless noted otherwise noted. 
Lenalidomide, pomalidomide, thalidomide, (+)-thalidomide, (-)-thalidomide, and 5HPP33 were obtained 
from Sigma-Aldrich. JQ1 was obtained from Jun Qi, Bradner lab. Stable isotope-labeled 15N2,
13C6-lysine 
(K8) and 15N4,
13C6-arginine (R10) and their natural abundance analogues were obtained from Cambridge 
Isotope Laboratories. Pluronic F-127, Octyl-beta glucoside and NDSB-195 were obtained from Santa 
Cruz. Fluorous silica resin (40um) was obtained from Fluorous Technologies.  
 
Cell culture and functional studies 
Cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (Brunswick, 
Germany). All cells were cultured in RPMI-1640 medium supplemented with penicillin/streptomycin 
and 10% fetal bovine serum, with the exception of CD34 cells cultured in SFEM supplemented with 
cytokines cocktails CC110 and CC200 from Stemcell Technologies (Vancouver, Canada). Suspension 
and adherent cells were maintained at a density of 0.5-1 million cells/ml or 50-90% confluence, 
respectively, at 37 ºC in a humidified atmosphere with 5% CO2. For metabolic labeling, cells were 
cultured for 6 doubling times in RPMI-1640 supplemented with either light or heavy isotope-labeled 
lysine and arginine and 10% dialyzed fetal bovine serum (Thermo Scientific) and checked by LC-
MS/MS for the presence of heavy labeled peptides. Cell counts were measured using the Neubauer 
hemocytometer (Hausser Scientific) or the Countess (Invitrogen) with Trypan Blue staining (Invitrogen) 
DFFRUGLQJWRPDQXIDFWXUHU·VLQVWUXFWLRQV 
Jurkat cells engineered to express GFP and KOPTK1 cells expressing shRNA targeting control 
GFP were generated by retroviral transduction as described (Cepko et al., 2001).  
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For analysis of fluorous lenalidomide cell penetration, cells were treated with fluorous 
lenalidomide for 1 hour and immediately lysed in RIPA buffer supplemented by protease and 
phosphatase inhibitors (Sigma), and both media and cell fractions were qualitatively assessed for 
presence of lenalidomide in a TOF-LCT mass spectrometer coupled to a Waters 2690 LC and 2996 
photoiodide detector (Waters, Milford, MA).  
Cell growth kinetics were measured by seeding cells in a 96-well plate, 10,000 cells per well, with 
or without the presence of drug or DMSO control. Cell counts were obtained using CellTiter-Glo 
(Promega) at intervals of 1 or 4 days read as per instructions on a FlUOstar Omega microplate reader 
(BMG Labtech). 
 
Synthetic chemistry  
Biotinylated JQ1 and fluorous JQ1 were obtained from Jason Marineau, Bradner Lab. An initial stock of 
fluorous lenalidomide was also obtained from JJM.  
 For synthesis of a second generation fluorous lenalidomide probe, lenalidomide (55mg, 0.212 
mmol) was dissolved in THF with 47.687mg sodium iodide (1.5 eq, 0.318 mmol), 5.5992 mg NaH (1.1 
eq, 0.2333 mmol) and 32.63mg 5-chloro-pentyne (1.5 eq, 0.3115 mmol) at 0.05M in 4.242mL THF. The 
reaction was quenched with saturated aqueous sodium bicarbonate and the aqueous layer extracted three 
times with ethyl acetate. Combined organic extracts were washed with brine, dried over sodium sulfate 
and concentrated, but failed to yield a significant fraction going forward unlike previous reports (Stewart 
et al., 2010). 
 In a second attempt, 50mg of lenalidomide (0.1929 mol) was dissolved in 0.9409 mL of THF 
(0.05M). 117.62 mg of triethylamine (6eq, 1.1574 mmol), 0.47 mg of DMAP, and 50.5mg of di-tert-butyl 
dicarbonate (f-boc) (1.1 eq, 0.231mmol) were added to the reaction and allowed to stir overnight, after 
which an additional 15mg (0.3eq) f-boc was added empirically to the reaction mixture. The reaction was 
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quenched with ice and water and extracted twice with ethylacetate, water and brine. The previously 
attempted reaction was repeated with excess NaH (3eq) and run and extracted as previously described. 
The reaction was purified by HPLC with an eluting gradient of 0-100% methanol in dichloromethane 
and afforded 8mg of yellowish solid. At this point work was stopped on further synthesis of a second 
generation probe.  
 For the synthesis of additional fluorous lenalidomide, lenalidomide (50 mg, 0.193 mmol, 1.1 
equivalent) was dissolved in dichloromethane (2.5 mL, 0.05 M). Perfluorooctylethylisocyanate (55 mg, 
0.113 mmol, 1 equiv.) was added, followed by diisopropylethylamine (20 uL, 0.113 mmol, 1 equiv.). The 
reaction was stirred under an inert atmosphere for 18 hours and then concentrated. The residue was 
purified by fluorous solid phase extraction using a 2g/8cc FluoroFlash cartridge (Fluorous Technologies 
Inc., USA) equilibrated with 80:20 methanol:water (2 X 3 mL). The residue was loaded as a solution in 2 
mL DMSO. The column was then washed with 80:20 methanol:water (2X3mL) and the fluorous 
product eluted with tetrahydrofuran (2 X 3 mL). The fluorous fraction was concentrated to afford 6 mg 
of a white solid. 
 Fluorous perphenazine, for proof of concept, was graciously provided by Alex Kenstis and 
Jason Marineau.  
 All reactions were followed on a Waters TOF-LCT MS coupled to Waters 2690 LC and Waters 
2996 photoiodide detector.  
 
Cell lysis and protein extraction  
Harvested cells were washed once with cold phosphate-buffered saline, and frozen at -80 ºC for 12 
hours. Thawed cells were resuspended in cold 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, supplemented 
with EDTA-free protease inhibitors (Roche) and 1% (v/v) detergents as indicated. For comparison of 
mechanical disruption methods, suspensions of 100 million cells in 1.8 ml of lysis buffer were processed 
20 
 
by using 20 strokes of the 2 ml Potter-Elvehjem homogenizer on ice (Corning) or disruption using the 
Covaris E210 adaptive focusing acoustic sonicator and 13x65 mm tubes operating in the frequency 
sweep mode at 1000 Hz, 20% duty cycle, and intensity 8 for 600 seconds at 4 ºC, or incubation at 95 ºC 
for 5 min in the lysis buffer supplemented with 1% SDS. All lysates were clarified by centrifugation at 
16,000 g for 10 minutes at 4 ºC. Protein concentration was measured using the bicinchoninic acid assay 
DFFRUGLQJWRPDQXIDFWXUHU·VLQVWUXFWLRQVDQGUHDGRQDW%LR5DG%HQFKPDUN3OXVVSHFWURSKRWRPHWHU
plate reader.  
 
Assessment of protein activities 
For GFP-expressing cells, GFP activity was measured using fluorescence emission spectroscopy with 
excitation of 488 nm and emission at 530 nm using 96-well plates (200 uL lysate/well) and the 
FLUOstar Omega plate reader.  
 
Western Blot 
Anti-CRBN antibodies were obtained from ProteinTech (rabbit polyclonal, whole peptide) and Abcam 
(mouse polyclonal, amino acids 1-442; rabbit polyclonal, N-termius 1-33) and used as per manufacturers 
instructions. Anti-rabbit and anti-mouse secondary antibodies conjugated with horseradish peroxidase 
were obtained from Thermo, and visualized using SuperSignal West Femto Chemiluminescent substrate, 
DFFRUGLQJWRPDQXIDFWXUHU·VLQVWUXFWLRQV7KHUPR,PDJHGHQVLWRPHWU\ZDVSHUIRUPHGXVLQJ,PDJH-
(NIH). 
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Drug affinity chromatography 
Biotinylated JQ1 was immobilized using NeutrAvidin UltraLink resin (Thermo Scientific) by incubating 
100 uL of resin slurry (0.005 umol of avidin) with 10uL of 10 mM solution of PPZ-biotin in DMSO (0.1 
umol) and 900 uL of Lysis buffer with 1% (w/v) Pluronic F-127 and 1% (w/v) octyl-beta-glucoside (PO 
buffer) at room temperature for 30 minutes on shaking mixer. For fluorous affinity chromatography, 40 
um FluoroFlash silica resin (Fluorous Technologies) was incubated in 80% aqueous methanol for 15 
minutes at room temperature in a shaking mixer, and wetted resin was washed twice with PO buffer. 
Washed resin was then incubated with fluorous JQ1 or lenalidomide in PO buffer, and drug-bound 
resins were washed 5 times with PO buffer, added to 3-5mg of clarified cell lysates diluted to 1.8 ml final 
volume with PO buffer either in the presence of 500 uM free competitor drugs dissolved in DMSO 
(light isotope-labeled proteome) or DMSO alone (9% v/v, heavy isotope-labeled proteome), and 
incubated while rotating at 4 ºC overnight. Protein-bound resin was washed 3 times with PO buffer, 
pooled to combine heavy and light-labeled fractions, and bound proteins were eluted by incubating 
resins in 0.2 ml of 8M urea, 50 mM Tris-HCl, pH 7.5 for 30 minutes at room temperature while on 
shaking mixer.  
 
Protein purification 
Urea-eluted proteins were purified by addition of 1 ml of cold chloroform:methanol (2:1) to extract 
residual detergent, and mixtures were centrifuged at 16,000 g for 15 minutes at 4 ºC. Protein discs at the 
organic:aqueous interface were transferred to a new tube and washed with cold acetone. Alternatively, 
peptides were precipitated by addition of 400 uL methanol followed by 100 uL choloroform and 300 uL 
water. An additional 400 uL of methanol was added, lysates were cleared at 16,000g and the protein was 
washed twice with acetone. After drying, peptides were dissolved in 70 uL of 0.1% (w/v) RapiGest 
(Waters) in 50 mM ammonium bicarbonate, pH 8.5 (ABC buffer) by incubating for 30 minutes at 37 ºC 
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while on a shaking mixer. Solubilized proteins were reduced with 5 mM dithiothreitol by incubation for 
45 minutes at 56 ºC, and alkylated with 15 mM iodoacetamide by incubation at room temperature for 30 
minutes in the dark. Proteins were subsequently digested with 2 ug porcine trypsin (Promega) by 
incubation at 37 ºC for 18 hours. RapiGest was removed by hydrolysis with 200 mM HCl at 37 ºC for 
45 minutes and centrifugation at 16,000 g for 20 minutes. Tryptic peptides were purified by reverse 
phase chromatography using C18 SpinTips and 0.1% TFA wash, according WRPDQXIDFWXUHU·V
instructions (Nest Group), and concentrated using vacuum centrifugation. 
 
Peptide mass spectrometry, identification and quantitation 
Tryptic peptides were dissolved in 5% (v/v) aqueous acetonitrile and 0.1% (v/v) formic acid and were 
resolved and ionized using nanoflow HPLC (nanoLC, Eksigent) coupled to the LTQ or LTQ-Orbitrap 
hybrid mass spectrometer (Thermo). Nanoflow chromatography, electrospray ionization and data-
dependent acquisition were performed as described, with the resolution of 60,000 and m/z range of 350-
2000 (Kentsis, 2009). Recorded mass spectra were searched against the International Protein Index 
database (version 3.91) that included reverse decoy sequences by using the Andromeda algorithm as 
implemented in MaxQuant (version 1.0.13.13) (Cox, 2011) for heavy/light quantification or by 
ProteinPilot (Applied Biosystems) for peptide ID (also against IPI 3.91). Variable modifications for N-
acetylation, methionine oxidation, and fixed cysteine carbamidomethylation were included. Mass 
tolerance for precursor and fragment ions was 10 ppm and 0.8 Da, respectively, with the false discovery 
rate of 1% at the peptide and protein levels. For quantitation, identified peptides were filtered to include 
only those with matched light and heavy isotope spectra, and peptide intensities were averaged for the 
highest ranking protein mappings to calculate relative abundances of light and heavy proteins, 
respectively. Gene Ontology (GO) annotations were computed using DAVID (version 6.7).  
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Zebrafish drug treatment experiments  
Fish were kept at 28.5 ºC on a 14-h light/10-h dark cycle, and embryos were obtained from the Look 
Lab as described previously (Etchin, 2011). For drug treatment, 10mM stock was added to a final 
concentration of 400-10uM thalidomide to 60-100 embryos in E3 medium. Zebrafish embryos were 
dechorionated prior to drug treatment at 6hpf by incubation in E3 medium containing 5mg/mL pronase 
(Sigma) for 3 minutes at room temperature, then washed five times with E3 medium. Embryos were 
immediately transferred to E3 medium containing drug. Every 6 hours during growth at 28.5 ºC 
embryos were checked by light microscopy for morphogenic alterations as previously described (Ito et 
al., 2010). At 75hpf embroys were fixed in 4% paraformaldehyde in PBS, washed with PBS, transferred 
to 100% methanol, and stored at -20ºC overnight. When ready to be examined, embryos were immersed 
in 50% MeOH in PBST for five minutes, 30% MeOH for another 5%, rinsed, and fixed again for 20 
minutes in PBS at RT. After rinsing, they were processed either for in-situ staining (not reported in this 
study) or simple examination (reported).  
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Results 
Selection of proof-of-method problems for fluorous proteomics 
We wished to test novel methods in the isolation, purification, and identification of peptides via drug 
affinity chromatography. To do so, as described above, we searched for drugs of suitable interest to test 
our platform. The ideal drug would be of biological or clinical interest, have substantive outstanding 
questions about its intracellular binding profile, have some reported binders to serve as internal positive 
controls, and have relatively rich background chemical literature to establish a theoretical SAR which 
might be confirmed in our own experiments. 
We settled on two drug-systems that we felt best fit these criteria: thalidomide analogs and 
bromodomain inhibitors such as JQ1. In both cases we performed a thorough review of the chemical 
literature, which included the establishment of a putative structure-activity relationship (SAR) for 
derivatives of thalidomide (see Table S1). The individual approaches to these drugs, combined with 
fluorous proteomics development, are described below. 
 
Lenalidomide has cell-autonomous tumor activity 
We first investigated thalidomide analogs. The mechanism of action of thalidomide derivatives has been 
extensively discussed in the literature, but no consensus exists as to the exact biochemical genesis of the 
anti-tumor activity which makes this class so therapeutically valuable. This made it an ideal drug class 
with which to test innovations in target ID: there is a significant background literature of observed 
effects and widespread clinical use of the drug class, but no direct observations of protein-drug 
interactions through proteomic approaches. New derivatives are in clinical development with only 
slightly altered chemical properties (Lacy et al., 2009; Lacy et al., 2010), and the class has been extensively 
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investigated for immunological properties as well, leading to a large stable of chemical data (Miyachi et 
al., 1997).  
Before beginning to investigate thalidomide, we wanted to verify for ourselves the anti-
proliferative effects of thalidomide and its derivatives. We first tested lenalidomide, the most commonly 
used anti-myeloma drug, in a variety of myeloma and leukemia cell lines by treating cell lines for 1 to 4 
days and observing inhibition of cell growth. At 1 day almost no growth inhibition was noted, so further 
experiments were carried out only at 4 days. The results are displayed in Figure 2A. Lenalidomide 
displayed an IC50 ranging from 15-30uM in various cell lines, but did not reach full inhibition of cell 
growth at concentrations up to 50uM, consistent with many prior reports. At any higher concentrations, 
DMSO was observed to inhibit cell growth in our assay and confound any possible observed drug 
effects. Three cell lines ² the dexamethasone-resistant myeloma cell line OPM1 and the leukemia cell 
lines KG-1 and HL-60 (Figure 2B) ² showed no inhibition at any tested concentration, consistent with 
UHSRUWVWKDWOHQDOLGRPLGH·VHIIHFWLVFHOO-line specific. Of note, lenalidomide inhibition requires high 
doses of drug, and also has an odd inhibition profile ² it does not show good specific inhibition, but 
rather a slow descent ² ERWKIDFWVSRVVLEO\LPSO\LQJDFRPSOLFDWHGEDVLVIRUOHQDOLGRPLGH·VLQKLELWLRQRI
cell growth, making it a problem of specific interest for high-specificity proteomics. It also has a fairly 
high IC50. We therefore decided to move forward with an investigation of thalidomide derivatives as a 
test of our strategy.  
 
Testing of other thalidomide derivatives establishes an SAR and identifies derivatives for further 
development  
Thalidomide has undergone extensive development and testing for a variety of interesting in vitro 
properties. Derivatives have been reported that have widely varying biological effects and efficacy with 
only small changes in overall chemical structure. To build a probe for target ID proteomics experiments 
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necessarily requires that a drug be chemically modified in some form by addition of a linker and tag. But 
not all positions on a drug are created equal, and some modifications are less disruptive to drug binding 
than others; thus careful attention to known differences between molecules with only slightly different 
chemical composition is critical to a successful target ID experiment. In addition, though thalidomide 
derivatives have been tested extensively for specific in vitro effects, much of the derivatization of 
thalidomide was done before thalidomide was a widely-used cancer treatment and was focused on other 
SURSHUWLHVVXFKDV´LPPXQRPRGXODWLRQµ7KXVVLJQLILFDQWNQRZOHGJHDERXWWKDOLGRPLGHGHULYDWLYHV·
effects on myeloma lines as compared to currently used drugs is lacking in all but a few cases. Finally, in 
VRPHDVVD\VWKDOLGRPLGH·VHIIHFWVDUHQRWVHHQXQOHVVWKDOLGRPLGHFDQEHPHWDEROL]HGEHIRUHUHDFKLQJ
its target cell (Price et al., 2002). Thalidomide metabolites, and not the drug itself, have therefore 
sometimes been considered the active species. One hypothesized metabolite in particular, 5-hydroxy-
thalidomide, has been proposed as the active drug.  
Therefore, to establish a SAR for thalidomide analogs biological effects, we tested a variety of 
thalidomide analogs for effects on the myeloma cell line MM1s. The structure of thalidomide analogs 
used is displayed in Figure 3A. Lenalidomide, discussed above, is the most widely used thalidomide 
derivative in a clinical setting. Pomalidomide, which is 4-amino-thalidomide (in the numbering scheme 
usually adopted in the literature; see Miyachi et al., 1997) has promising activity in clinical trials and is 
sometimes reported to have a higher IC50 than lenalidomide. 5HPP33 is from a class of thalidomide-
like molecules in which the glutaramide is replaced by a benzyl, which showed significant anti-
inflammatory activity in vitro. Significant differences have sometimes been observed between the 
stereoisomers of thalidomide, though they readily convert in vivo (Teo et al., 2003; Ito et al., 2010). 5-OH-
Thalidomide has already been mentioned as the potential active metabolite and shares some chemical 
features with 5HPP33 and lenalidomide in its addition of a hydroxyl or amine on the phthalimide ring. 
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The results of MM1s treatment with this panel of analogs is displayed in Figure 4A. 
Lenalidomide and pomalidomide showed IC50s of 35uM and 15uM, respectively, while both isomers of 
thalidomide and 5-OH-thalidomide showed almost no effect. (-)-Thalidomide, consistent with reports 
that it may be the active isomer, showed a very small anti-tumor effect (IC50 of ~500uM). Surprisingly, 
5HPP33 showed remarkable anti-tumor activity.  
Rationalizing an SAR from the biological effects observed in this small screen was difficult. The 
great increase in efficacy seen from the inclusion of an amino group on the phthalimide ring (in 
lenalidomide and pomalidomide) indicated that this region of the molecule was critical for activity, 
consistent with previous reports (Muller et al., 1999). On the other hand, replacement of the glutaramide 
ring with a similar benzyl-di-tert-butyl ring (in 5HPP33) also markedly increased the activity. Addition of 
a hydroxyl group in the five position did not appreciably alter the IC50 of thalidomide, but the same 
position hydroxyl appears, according to literature reports, to be required for 5HPPP33 (Noguchi et al., 
2005). In sum, no consistent pattern emerges from the data which would suggest one particular region 
of the molecule is primarily responsible for its intracellular binding profile.  
 
5HPP33 as a potential lead for drug development and Target ID 
We were interested in the robust inhibition displayed by 5HPP33 in our initial cell line tests, so we tested 
the same panel of thalidomide analogs against CD34+ control (non-transformed) cells to determine 
which thalidomide derivatives, if any, displayed evidence in vitro for a therapeutic index (Figure 4B). 
Notably, none of the thalidomide analogs other than 5HPP33 and (-)-Thalidomide showed any greater 
inhibition of cells than DMSO control alone. The IC50 of 5HPP33 was 232nM in MM1s and 23.7uM in 
CD34 positive control cells, defining a therapeutic index of 102.1; by comparison Gleevec has an in vitro 
therapeutic index ranging from 57 to 243 depending on tested cell line (Topaly et al, 2002). These results 
indicate that 5HPP33 may have unique anti-cancer properties in the thalidomide derivatives class and be 
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a lead for future drug development along these lines. It has been proposed as an inhibitor of tubulin 
polymerization (Iguchi et al., 2008) but was initially reported for its anti-immunogenic properties 
(Miyachi et al., 2007). Any other substituent of the benzyl ring on 5HPP33 smaller than a tert-butyl 
group fully disrupted its efficacy, suggesting this end of the molecule was critical for the effect of the 
drug.  
Despite the potential of 5HPP33 for novel development, we felt that the background literature 
and clinical use of lenalidomide, which shows no inhibition of CD34+ cells, was the most suited to 
further investigation by fluorous proteomics. We therefore chose to move ahead with lenalidomide as 
our primary drug of investigation.  
 
Lenalidomide in a zebrafish model  
Recent reports had relied on zebrafish models to identify the intracellular binders and effects of 
thalidomide by a proteomics experiment similar to the one we proposed to perform with lenalidomide. 
That same report included the observation of major morphogenic alterations during zebrafish 
development with thalidomide treatment (Ito et al., 2010). We therefore wondered whether 
lenalidomide, which in rabbit models has less teratogenicity than thalidomide, would also show smaller 
teratogenic effects in zebrafish than thalidomide. We had already observed the widely divergent profiles 
of lenalidomide and thalidomide on myeloma cell treatment, and an extra phenotypic comparison would 
prove additionally useful for later analysis of proteomics results. Specifically, if CRBN is the intracellular 
target of thalidomide that is responsible for its teratogenicity, and lenalidomide is not, in fact, 
teratogenic, it naturally suggests the hypothesis that lenalidomide has a different target than thalidomide 
(and therefore CRBN might not be robustly observed in proteomics experiments). If, on the other hand, 
lenalidomide is teratogenic, it suggests that CRBN may be its primary intracellular target and should 
show up in any proteomics screen of lenalidomide.  
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We therefore replicated previous experiments by treating WT zebrafish with lenalidomide at 
concentrations ranging from 400 to 25 uM as previously reported. Briefly, zebrafish were dechorionated 
at 4hpf and treated with drug continuously for up to 72 hours, observed by light microscopy, and fixed 
for in situ and further microscopy. During this time, we did not observe any of the previously reported 
teratogenic effects of thalidomide on zebrafish embryos. Specifically, both pectoral fins and otic vessels 
developed normally, while reported changes with thalidomide were observed as previously reported. 
It is possible that lenalidomide, which is slightly more polar than thalidomide, was being hydrolyzed or 
otherwise broken down in media, thereby lowering the concentration below requisite levels. The 
required dose of thalidomide treatment had previously been determined empirically and most of the 
major effects only seen at higher doses, so there was some concern. To alleviate this concern, we 
monitored the lenalidomide in the media by LC-MS over the time course of treatment, and observed no 
significant drop in concentration (data not shown). We concluded that lenalidomide does not have the 
teratogenic effects of thalidomide in a zebrafish model. Interestingly, high doses of lenalidomide were 
also tested in rabbits and found not to be teratogenic there (Christian et al., 2007). Given the new studies 
on lenalidomide mechanism cited in the introduction, it is a remarkable synthesis with our experiments 
that lenalidomide may have such divergent properties in this regard from lenalidomide.  
 
Synthesis and testing of a lenalidomide-fluorous probe 
With our data from both cell lines and zebrafish we therefore began the first steps towards a fluorous 
proteomics experiment involving lenalidomide by synthesizing a fluorous lenalidomide probe (Figure 
3B). Synthetic methods and yields are discussed in Methods. 
We chose to use the phthalimide amine on lenalidomide for our linker moiety for two reasons: 
ease of chemical access, and the evidence from 5HPP33 that steric effects on the glutaramide ring can 
effect major changes in the phenotypic profile of thalidomide derivatives. While differences have been 
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observed between hydroxyl and amino groups on the phthalimide (and their respective positions around 
the ring), this was not determined to be as critical of a concern.  
Once in possession of a fluorous lenalidomide (f-len) probe, we wondered whether the probe 
would show in vitro efficacy similar to lenalidomide. We therefore treated MM1s cells with f-len and 
lenalidomide (Figure 5). No inhibition was observed with f-len greater than DMSO control. We 
therefore wondered whether the fluorous tag was preventing intracellular efficacy ² which might be a 
major concern for proteomics experiments ² or whether the probe was simply failing to penetrate cells 
at a sufficient concentration due to the highly unique fluorous tag. We therefore treated cells for four 
days with lenalidomide, removed the media, lysed the treated cells, and looked for the presence of 
lenalidomide in both a cell and media fraction by LC-MS. After 4 days treatment with lenalidomide, 
both fractions showed significant presence of lenalidomide; after 4 days treatment with f-len, we did not 
observe any lenalidomide in the cell fraction though it was readily detectable in the media. We therefore 
concluded that f-len does not penetrate cells, and hoped that it might reliably recapitulate in vitro protein 
binding kinetics if used for proteomics experiments. 
 
Establishing experimental conditions for fluorous proteomics  
With a fluorous probe in hand, we wanted to be sure that we could perform a fluorous separation of 
drug and resin from a complex mixture before attempting to use the probe for protein isolation. We 
therefore added probe to biological media and lysate and washed the resulting mixture over fluorous 
resin. We then used LC-MS to identify any small molecules bound the fluorous resin, and observed only 
fluorous lenalidomide as the major binder. After elution and purification, we found that we could 
reliably recover 85% of the fluorous probe from the complex mixture we tested. We concluded, 
therefore, that fluorous pull-downs may work under typical proteomics conditions and might be relied 
upon to separate proteins from a complex mixture.  
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 To further ensure that the fluorous probe was robustly bound and would only elute under 
appropriate solvent conditions and not develop interference from a competing drug, we incubated 
another fluorous tagged molecule (perphenazine) which was readily available to us with flourous resin 
with or without the presence of competing unbound perphenazine in the mixture. We then washed the 
resin, eluted under typical experimental conditions, and observed whether we could recover a significant 
percentage of our original probe with mass spectrometry. We were indeed able to recover nearly all of 
the originally bound probe, and it was not at all effected by the presence of competing drug, which was 
easily washed away and did not bind the fluorous resin (Figure S1). This gave us further proof-of-
principle that our fluorous strategy was chemically specific and robust.  
We then turned our attention to optimal protein lysis conditions for use with a fluorous probe. 
Buffer conditions for the lysis and recovery of proteins have been investigated (Winkler et al., 2009), but 
we sought to define for ourselves an approach which would maximize the yield of protein in native 
conformation from the largest possible subset of cellular organelles. Generally, the harsher the buffer 
conditions, the larger the percentage of the proteome which can be recovered; at the same time, such an 
approach necessarily denatures a large number of proteins, making them unsuitable for drug-affinity 
proteomics. The optimal lysis conditions would preserve native activity while generating good yield of 
protein. 
We obtained Jurkat leukemia cells which had been engineered to express green fluorescent 
protein (GFP), which can readily be measured in cell lysates, as a rapid comparison method for the 
isolation of proteins with native activity. To quantify protein yield we performed a standard 
bicinchoninic acid assay.  
We tested a variety of proprietary commercial lysis media as well as traditional lysis buffer 
supplemented by a variety of detergents. The results are displayed in Figure 6. Consistent with previous 
reports, we found that the addition of non-ionic detergents NP-40 and Pluronic F-127 to native lysis 
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buffer greatly increased yield extraction and yield activity as compared to native buffer alone. Since 
mixtures of detergents have sometimes been used to increase extraction efficiency (Iwata et al., 2003), we 
also tested a variety of binary combinations of detergents. We found that the addition of the octyl-beta-
glucosidase to Pluronic F-127 showed a further increase in extraction efficiency to as high as 1% SDS 
without any of the denaturing effect observed with such a harsh treatment. We then tested fluorous 
probe recovery in this media, as described above, and saw f-len probe recovery equal to that which was 
observed in cell media (~85%), indicating that this buffer system was suitable for fluorous proteomics.  
 
Fluorous proteomics of lenalidomide 
With a suitable probe and proteome extraction conditions in hand, we lysed MM1s cells and separated 
the mixture by fluorous drug-affinity proteomics as displayed schematically in Figure 1A. Briefly, we 
incubated fluorous lenalidomide probe with lysates in the presence of fluorous resin, washed out 
unbound proteins, eluted, purified, and digested bound peptides with trypsin. Peptides were then 
injected into a mass spectrometer, and spectra were analyzed by ProteinPilot software for identification. 
A typical spectrum generated from an entire LC-MS/MS run is displayed in Figure 7A. Figures 7B and 
7C display typical statistical analysis of a single LC-MS/MS peptide identification run which was 
performed an analyzed after each sample to check for accuracy of peptide identification.   
 As expected, fluorous resin bound very few peptides in a non-specific manner. Only 31 non-
specific peptides were bound to fluorous resin (data not shown), roughly the same as in a blank sample, 
and including peptides such as keratin and actin which were commonly confounding in all experiments 
and can be easily removed from consideration for biological significance. Streptavidin resins, by 
contrast, generated up to roughly 200 non-specific interactions, even when using a resin specifically 
designed to minimize non-specific adsorption (Alex Kentsis, private communication). The contrast 
between the high specificity of fluorous and promiscuity of streptavidin gave us hope that we would be 
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able to specifically identify a large number of lenalidomide-binding peptides without the interference 
common in traditional drug-affinity proteomics. 
 We therefor performed fluorous affinity proteomics by incubating fluorous lenalidomide with 
and without the presence of competitor, eluted, and identified peptides. Quantification was performed 
using spectral counts and unique peptide calls were made by ProteinPilot with a reported confidence 
value for spectral matching. The results, after filtering only for peptides specifically bound to the probe, 
are displayed in Table 1. 
 Notably, we did not find CRBN to be a binder of our probe. We anticipated that given the 
structural similarity between the drugs, even if CRBN was not the major binder of lenalidomide as it is 
for thalidomide, we would at least see some CRBN bound to the probe. In this way we hoped it would 
act as an internal positive control for our experiment. Since no other specific proteins have been 
identified as binding lenalidomide or thalidomide, we had no further way of internally validating the 
results. To confirm that CRBN was not in fact in our sample and rule out the possibility that its signal 
was obscured during LC-MS/MS by higher-ranking binders, we obtained antibodies for CRBN and 
tested affinity-purified lysates as well as native MM1s lysates for the presence of CRBN. In both cases 
we did not observe CRBN signal. The anti-CRBN antibodies are polyclonal and not well-validated, and 
we did not proceed further to validate them; nonetheless, it remains possible that CRBN was simply not 
part of the proteome of MM1s cells at sufficient levels to be detected by our experiments.  
 The list of identified peptides was submitted to DAVID for GO term analysis, and found to be 
overrepresented for proteins involved in nucleotide binding, mitochondrial space, and induction of 
apoptosis (all p<.0001). Notable genes included apoptosis inducing factor, chromodomain-helicase 
binding protein 7, and Gas1, which have been elsewhere associated with cancer or developmental 
diseases (Martinelli and Fan, 2007; Bajpai et al., 2010). 
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 Soon after we completed this experiment, it was reported the CRBN indeed bound lenalidomide 
LQDQRWKHUJURXS·VZRUN(EHUWODESULYDWHFRPPXQLFDWLRQ:LWKRXWREVHUYLQJ&5%1LQRXUVWXGLHV
we were unsure as to the validity of the rest of our identifications. Therefore, in order to continue 
testing fluorous proteomics, we moved on to repeating the procedure with a second drug for Target ID, 
the BET  bromodomain inhibitor JQ1.  
 
JQ1 in T-ALL 
The novel thieno-triazolo-1,4-diazepine JQ1 (Figure 8) binds selectively and with high affinity to the 
acetyllysine binding pocked of the conserved bromodomain and extra-terminal domain (BET) protein 
family, comprised of BRD2, BRD3, BRD4 and BRDT. BRD3 and BRD4 are translocated with the 
NUT gene in a rare form of squamous carcinoma (French et al., 2008), and an RNAi screen identified 
BRD4 as a potential therapeutic target in acute myelogenous leukemia (Zuber et al., 2011). Notably, 
inhibition of BRD4 is thought to selectively disrupt malignant cells by downregulating chromatin-
mediated signal transduction at several loci, including MYC, which encodes the oncoprotein c-Myc.  
 JQ1 has been under investigation in several other cancer types and has recently shown potential 
in the treatment of T-ALL in vitro. Similar to our strategy with lenalidomide, we treated KOPTK1 cells 
(a T-ALL cell line) with JQ1 to establish its pharmacological profile (Figure 9). We found robust 
inhibition of KOPTK proliferation with an IC50 of 130nM, two orders of magnitude higher than 
lenalidomide. We hoped the more specific binding of JQ1 would allow for a better proof-of-method for 
fluorous drug affinity proteomics and the work on JQ1 in T-ALL elsewhere in the lab would find a 
good counterpoint in fluorous proteomics data generated for JQ1.   
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Biotinylated JQ1 drug-affinity chromatography 
We obtained fluorous and biotinylated JQ1 probes for a direct method comparison between fluorous 
and biotin-based identification (kindly provided by Jason Marrineau, Bradner Lab). The structure of the 
probes is displayed in Figure 8 (only fluorous probe shown; biotin probe synthesis is discussed in a 
publication in press and not presented here).  
 We performed the previously reported drug-affinity/peptide identification protocol, first with 
biotinylated JQ1. The results of this pull down are displayed in Table 2. We observed a significant 
number of non-specifically bound peptides (157), consistent with expectations for a streptavidin matrix. 
Nonetheless, once filtering out for non-specific interactions, we were able to identify the known binders 
of JQ1 (BRD2, BRD3, BRD4) as well as many other potential binders of equal significance. HSPA1A, 
HSPA8 and TUBB have all been associated with cancer; GO term analysis revealed significant 
overrepresentation of proteins annotated for involvement in acetylation, translation, MHC class 1 
binding and microtubule polymerization (p<1e-26). Notably several ribosomal proteins associated with 
Diamond-Blackfan anemia (RPL11, 17, 19 and 7) were also identified, as well as pyruvate kinase M2, 
which has been widely reported in recent literature as critical to the pathogenesis of many cancers 
(Vander Heiden et al., 2009). Several heat shock proteins on the list have also been identified as playing a 
role in various diseases.  
 
Fluorous proteomics of JQ1.  
Encouraged by the observation of positive internal controls as well as potential novel binders of JQ1 
using the biotinylated probe, we performed fluorous drug-affinity chromatography on f-JQ1. Using 
SILAC-labeled cells, we quantified and identified specific binders to fluorous-JQ1 following the 
previously described methods and generated a list of bound peptides (Table 3).  
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 Surprisingly, while we found many specific binders of fluorous JQ1, we could not identify a 
similar list of bound proteins to biotinylated JQ1 (which we had high confidence in as it included many 
of the known binders). A huge list of peptides was identified, only the top 100 of which were included 
in Table 3. BRD2, BRD3, and BRD4, the known binders of JQ1 which were visible in the biotinylated 
JQ affinity-chromatography, were not seen with fluorous JQ1. Still, the list that was obtained had a 
number of binders in common with the JQ1 biotin list, including pyruvate kinase, though this may be a 
result of fair abundance of pyruvate kinase in cellular extracts. Notably the SET gene, which has been 
previously implicated in myeloid malignancies, was also identified (Nagata et al., 1995). Functional 
annotation showed overpresentation of genes involved in acetylation and methylation (p<1e-20), raising 
the confidence that the list contains genes related to JQ1 activity.   
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Discussion 
Summary 
In this work, we attempted to apply a novel technique, which we termed fluorous-affinity protetomics, 
to the traditional problem of drug-affinity chromatography for target ID. We chose two drugs, 
thalidomide and JQ1, as proof-of-concept systems with which to work. We established the 
pharmacokinetic profile of each in the cell lines of interest, determined for thalidomide which drug to 
test from a group of analogs, and designed probes based on our best-guess SAR for thalidomide. 
 We then established the conditions for fluorous proteomics and tested the applicability of the 
fluorous technique at several intermediate steps. At the same time we investigated the biology of 
lenalidomide and JQ1, identifying in the case of the former a novel analog 5HPP33 which shows 
therapeutic potential, and establishing the applicability of JQ1 to treatment of T-ALL.  
 We investigated both lenalidomide and JQ1 by fluorous proteomics with biotinylated JQ1 as a 
control. In each case, we identified a list of specifically bound peptides, but we did not consistently 
observe the known (or putatively known) binders in our samples (CRBN and the BRD family). As we 
were unsure of the value of our results, we chose to continue refining and repeating our screen 
technique rather than validating potential novel binders, except in the case of Biotin JQ1, where we 
observed proteins we were sure bound to JQ1, making this our highest-confidence list of identified 
peptides. Nonetheless, we identified a robust list of interesting proteins by fluorous proteomics, some of 
which had known association with disease. 
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The mechanism of lenalidomide  
When we initially set out on our experiments above, we attempted to both (1) develop a novel 
technology for target ID and (2) leverage that technology toward solving an important biological and 
chemical problem, the mechanism of action of lenalidomide. As noted in the introduction, several recent 
papers have had a major bearing on this second aim by in fact offering a solution to this problem. One 
of these papers also solved the crystal structure of lenalidomide in complex with CRBN and DDB-1 
(Chamberlain et al., 2014). In this paper, Chamberlain and colleagues note that lenalidomide is 
accommodated to CRBN in a tri-tryptophan hydrophobic pocket, with the glutaramide ring of 
lenalidomide sliding into this pocket and the pthalidmide (isoindolinone) group (which is differentially 
modified in lenalidomide and pomalidomide versus thalidomide) is exposed at the surface of the protein. 
The authors of this paper note that this binding pocket is highly conserved in orthologs of cereblon, 
implying that perhaps an as-\HWXQLGHQWLILHGQDWXUDOOLJDQGPD\RFFXS\WKLVVSDFHDVDQ´DGDSWRU-OLNHµ
molecule for facilitating specific ubiquitination. It is intriguing, given these results, that 5HPP33, which 
replaces the glutaramide with the highly nonpolar but similarly-sized di-tert-butyl-benzyl group, is a very 
effective inhibitor of myeloma cell growth in our experiments (Figure 3A and 4A). The benzyl could 
very effectively hit this same pocket. An outstanding question ² and one with great potential 
implications for drug design ² is whether lenalidomide and its derivatives present a neomorphic 
structure for selective ubiquitination that is not a normal function of the protein. Evidence from other 
papers (Ito et al., 2010) implies, but does not prove, that thalidomide works through creating a 
hypermorph (i.e., RNAi experiments knocking-down CRBN recapitulate the thalidomide phenotype 
seen in chicks and zebrafish). Given that lenalidomide and thalidomide, as shown here and previously, 
have some vastly different phenotypes (differences in teratogenicity in zebrafish shown here; rabbits as 
noted previously; differential induction of IL-2 in recent work), it is tempting to speculate that minor 
alterations tRWKLVPROHFXOHFRXOGHQDEOHLQWULJXLQJQHZSURSHUWLHVDQGLQGLUHFWO\GUXJJDEOH´WDUJHWVµ
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Control of ubiquitination may be a new frontier in drug design, and evidence presented here in 
lenalidomide derivatives both extends, supports, and offers intriguing new possibilities for this line of 
work.   
Difficulties (and possible successes) with fluorous proteomics 
The greatest disappointment in our work was the variable quality of outcome of peptide ID. In several 
experiments, we observed a robust list of interesting proteins bound to our probe. Nonetheless we failed 
to observe, in the case of both fluorous probes, the expected internal positive controls ² peptides 
known to bind to our probe as high hits on our screen.  
 ,WLVSRVVLEOHWKDWZHZHUHVLPSO\´XQOXFN\µLQRXUSUREHGHVLJQ/HQDOLGRPLGHLVan extremely 
complex molecule, and a simple SAR is almost impossible to derive from the literature (see Table S1) or 
from our own experiments; from the recent experiments, it seems as if putting our linker on the 
SWKDOLPLGHZDV´FRUUHFWµIURPDVWUXFWXUDOOLJDQG-protein relationship view, but it is impossible to know 
how the size of the linker would affect the binding of the glutaramide to the putative tri-tryptophan 
pocket discussed just above.  
Our probe was designed chiefly for ease of chemical synthesis, but any piece of the probe ² the 
amide coupling, the linker length, its placement on the phthalimide amine, using amide rather than 
another form of coupling to linker ² could conceivably alter the chemistry of lenalidomide so that it did 
not bind its normal in vivo targets in our experiments. In any event, it shows the sensitivity of proteomics 
experiments to all downstream aspects of the experimental set up, and the great biological diversity that 
might be revealed (sometimes unintentionally) when pursuing these experiments. Such diversity can, as 
in this case, be a confounder that makes troubleshooting as difficult as the diversity itself might be 
illuminating.  
 The comparison between biotinylated JQ1 and fluorous JQ1 was likewise by equal measures 
disappointing and intriguing. With a biotin probe we observed all three of the known binders to JQ1 in 
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KOPTK cells (BRD2, BRD3, and BRD4), in addition to a long list of even more tightly bound peptides 
which may be of continuing interest to the JQ1 field going forward. Several have association with 
disease, cancer, translation and acetylation; some are likely members of the histone reader complex (and 
thereby co-purified with the BRD proteins) that have not yet been fully identified in other experiments. 
Of particular note here was the high spot of pyruvate kinase M2 on this list.  
 On the other hand, fluorous proteomics in the same cell system and under the same conditions 
did not show any of the BRD proteins, though it did share a number of other identifications in common 
with the biotin probe. Why would the fluorous and biotin lists diverge so completely? It is possible that 
the fluorous resin, while minimizing non-specific interactions, loses some measure of stabilizing effect 
on peptides that is present with a streptavidin resin; and that while tag-matrix interactions may be 
stronger in the fluorous case (and protein-matrix interactions weaker), somehow the protein was washed 
away during our experimental set up due to this weak binding. Without further experiments, especially 
additional SILAC or tag-based quantitation, it is difficult to say more about the possible failings of 
fluorous proteomics. The major future directions that could develop out of this work are (1) a further 
investigation of fluorous proteomics, including troubleshooting; and (2), a validation of any novel targets 
observed in the experiments contained here.  
We were encouraged by the prospects of fluorous proteomics. But future, more controlled 
experiments might be required for validation of the technique itself, in which the balance of problems 
FKRVHQVKLIWVVOLJKWO\IURP´NQRZQDQGXQNQRZQELRORJ\µZKLFKZHFKRVHWRPD[LPL]HERWK
biological interest and method validation) closer to the realm oI´IXOO\NQRZQELRORJ\µFluorous 
proteomics may still hold great potential for target ID, but we would proceed with caution.  
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